BioPoint Inc

06/05/2026

Eli Lilly and Company and Novo Nordisk highlighted new obesity data at ADA 2026 as competition in the weight-loss market intensifies. Other drugmakers are also advancing programs to challenge the market leaders. https://www.biospace.com/lilly-novo-face-off-at-ada-2026-as-others-seek-to-compete-in-obesity

The American Diabetes Association's annual congress will feature a superstar lineup, including weight loss giants Eli Lilly and Novo Nordisk. But several scrappy biotechs will also present obesity candidates with the potential to match—if not outperform—their deep-pocketed competitors.

06/04/2026

Massachusetts life sciences employment declined in 2025, ending a 14-year streak of industry job growth. The slowdown reflects broader challenges facing the biotech sector. https://www.biospace.com/job-trends/massachusetts-life-sciences-employment-dipped-last-year-following-14-years-of-growth-report

Massachusetts’ life sciences jobs declined 1% in 2025, according to a new MassBioEd report. However, the report is projecting industry employment will increase 9.7% by 2030. It also noted reskilling needs for some roles, including scientists.

06/03/2026

Travere Therapeutics signed a deal worth up to $1.1B to expand its rare kidney disease portfolio. The agreement strengthens its presence in the rare disease market. https://www.biospace.com/deals/travere-beefs-up-rare-kidney-disease-portfolio-with-up-to-1-1b-china-deal

Travere Therapeutics will gain an exclusive license to the oral BTK inhibitor civorebrutinib, which analysts at Guggenheim Securities said could be “complementary” to the biotech’s IgA nephropathy drug Filspari.

06/02/2026

The FDA is reevaluating its priority review voucher program as lawmakers consider bringing the incentive back into focus. The discussion could impact how companies accelerate drug approvals in the future. https://www.biospace.com/fda/fda-policy-tracker-2026-priority-vouchers-questioned-prvs-return

A year of significant policy change at the FDA brought momentum and scrutiny into the new year. As 2026 gets underway, biopharma companies are responding to sweeping vaccine changes while concerns surface about the politicization of the agency.

06/01/2026

Seventeen companies are expected to create more than 400 new jobs across Massachusetts, signaling continued growth in the state’s biotech sector. Most of the planned hiring comes from expanding life sciences and drug development operations.
https://www.biospace.com/job-trends/17-companies-expected-to-create-400-massachusetts-jobs-add-under-50

05/29/2026

Replimune Group is making a third attempt to gain FDA approval for its cancer immunotherapy following recent leadership changes at the agency. The company hopes the regulatory shift could improve the therapy’s chances of approval. https://www.biospace.com/fda/replimune-gives-cancer-immunotherapy-a-third-try-after-fda-leadership-shakeup

Replimune’s resubmission for RP1 for melanoma comes amid the departures of FDA leaders in place at the time of the drug’s first two rejections, last summer and again in April.

05/28/2026

GSK and Ionis Pharmaceuticals reported that their hepatitis B therapy functionally cured nearly 20% of patients in a clinical trial. The results mark a promising step toward reducing long-term dependence on chronic hepatitis B treatments. https://www.biospace.com/drug-development/gsk-ionis-hepatitis-b-functional-cure-effectively-eliminates-virus-in-nearly-20-of-patients

The antisense oligonucleotide was even more effective in patients with relatively low viral activity. More than one-quarter of these individuals had undetectable levels of the virus in the blood for at least six months after stopping treatment.

05/26/2026

Eli Lilly and Company expanded its vaccine pipeline with three biotech acquisitions valued at up to $3.8B. The deals strengthen Lilly’s position in next-generation vaccine development. https://www.biospace.com/business/lilly-lands-vaccine-trifecta-with-3-new-biotech-buys-valued-at-3-8b

Eli Lilly, with a busier-than-ever business development team, has made a major vaccine play‚ months after hiring veteran vaccine regulator Peter Marks following his FDA departure.

05/25/2026

On this Memorial Day, all of us at BioPoint extend our deepest gratitude to those who gave their lives in defense of the freedoms we enjoy every day, and to the families who carry their legacy forward.

05/21/2026

Roche signed a licensing agreement allowing generic manufacturers to produce its antiviral flu drug. The move is intended to expand global access and increase supply availability. https://www.biospace.com/news/roche-licensing-pact-clears-generic-drugmakers-to-manufacture-antiviral-flu-drug

By partnering with a UN-backed body, Roche has enabled companies to make the medicine for supply in 129 countries.